Literature DB >> 29961859

Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.

Donn J Colby1, Eugene Kroon1, Carlo Sacdalan1, Monica Gandhi2, Robert M Grant2, Praphan Phanuphak1, Jintanat Ananworanich3,4, Merlin L Robb3,4, Nittaya Phanuphak1.   

Abstract

We report a case indicating that acquisition of multidrug-resistant human immunodeficiency (HIV) virus type 1 during preexposure prophylaxis with combination tenofovir disoproxil fumarate and emtricitabine or evolution of resistance after HIV seroconversion remains a risk.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29961859      PMCID： PMC6117447          DOI： 10.1093/cid/ciy321

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Authors:  David C Knox; Peter L Anderson; P Richard Harrigan; Darrell H S Tan
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

3.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

4.  Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.

Authors:  Mariya V Sivay; Maoji Li; Estelle Piwowar-Manning; Yinfeng Zhang; Sarah E Hudelson; Mark A Marzinke; Rivet K Amico; Andrew Redd; Craig W Hendrix; Peter L Anderson; Kevin Bokoch; Linda-Gail Bekker; Frits van Griensven; Sharon Mannheimer; James P Hughes; Robert Grant; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.731

5.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Authors:  Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-15       Impact factor: 2.205

6.  Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Authors:  Martin Markowitz; Howard Grossman; Peter L Anderson; Robert Grant; Monica Gandhi; Howard Horng; Hiroshi Mohri
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

7.  Declining trend in transmitted drug resistance detected in a prospective cohort study of acute HIV infection in Bangkok, Thailand.

Authors:  Donn J Colby; Trevor A Crowell; Sunee Sirivichayakul; Suteeraporn Pinyakorn; Eugene Kroon; Khunthalee Benjapornpong; Jintana Intasan; Rapee Trichavaroj; Sodsai Tovanabutra; Merlin Robb; Praphan Phanuphak; Jintanat Ananworanich; Nittaya Phanuphak
Journal:  J Int AIDS Soc       Date:  2016-10-31       Impact factor: 5.396

8.  Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).

Authors:  Albert Y Liu; Qiyun Yang; Yong Huang; Peter Bacchetti; Peter L Anderson; Chengshi Jin; Kathy Goggin; Kristefer Stojanovski; Robert Grant; Susan P Buchbinder; Ruth M Greenblatt; Monica Gandhi
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

9.  Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy.

Authors:  Olubanke Davies; Hannah Alexander; Nicola Robinson; Matthew Pace; Michael Brady; John Frater; Julie Fox
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321
  10 in total
  18 in total

Review 1.  Drug Resistance During HIV Pre-Exposure Prophylaxis.

Authors:  Kevin M Gibas; Polly van den Berg; Victoria E Powell; Douglas S Krakower
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

2.  Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.

Authors:  Stephanie E Cohen; Darpun Sachdev; Sulggi A Lee; Susan Scheer; Oliver Bacon; Miao-Jung Chen; Hideaki Okochi; Peter L Anderson; Mary F Kearney; Susa Coffey; Hyman Scott; Robert M Grant; Diane Havlir; Monica Gandhi
Journal:  Lancet HIV       Date:  2018-11-29       Impact factor: 12.767

Review 3.  Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation.

Authors:  Victoria E Powell; Kevin M Gibas; Joshua DuBow; Douglas S Krakower
Journal:  Curr Infect Dis Rep       Date:  2019-06-21       Impact factor: 3.725

4.  Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.

Authors:  Raphael J Landovitz; Sue Li; Joseph J Eron; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Manya Magnus; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Paul Richardson; Mark A Marzinke; Susan H Eshleman; Ryan Kofron; Adeola Adeyeye; David Burns; Alex R Rinehart; David Margolis; Myron S Cohen; Marybeth McCauley; Craig W Hendrix
Journal:  Lancet HIV       Date:  2020-06-01       Impact factor: 12.767

Review 5.  Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.

Authors:  Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

Review 6.  How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?

Authors:  Urvi M Parikh; John W Mellors
Journal:  Curr Opin HIV AIDS       Date:  2022-07-01       Impact factor: 4.061

7.  HIV-1 Nucleic Acids Identify Rectal HIV Exposures in Self-Collected Rectal Swabs, Whereas Y-Chromosome Single Tandem Repeat Mixtures Are Not Reliable Biomarkers of Condomless Receptive Anal Intercourse.

Authors:  Maria P Lemos; Vijay Nandi; Joan Dragavon; Ira Fleming; Keertana Krishnan; Martin Musuruana; Madeline Kramer; Hayley Glantz; Michele Andrasik; Robert W Coombs; M Juliana McElrath; Hong-Van Tieu
Journal:  J Acquir Immune Defic Syndr       Date:  2021-10-01       Impact factor: 3.771

8.  Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project.

Authors:  Lisa Levy; Jill M Peterson; Lauren D Kudrick; Bhavna Chohan; Everline Bosek; Irene Mukui; Mary Mugambi; Sarah Masyuko; Owen Mugurungi; Nonhlanhla Ndlovu; Imelda Mahaka; Megan Dunbar; Anita Hettema; Rudo A P Kuwengwa; Sindy Matse; Saiqa Mullick; Letitia Greener; Cara O'Connor; Diantha Pillay; Maria Fawzy; John W Mellors; Urvi M Parikh
Journal:  Glob Health Sci Pract       Date:  2022-04-29

9.  Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.

Authors:  Matthew A Spinelli; Brentton Lowery; Jennifer A Shuford; Jon Spindler; Mary F Kearney; Jenny R McFarlane; Cheryl McDonald; Hideaki Okochi; Nhi Phung; Karen Kuncze; Kathryn Jee; DeeJay Johannessen; Peter L Anderson; Dawn K Smith; Patricia Defechereux; Robert M Grant; Monica Gandhi
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 20.999

10.  Brief Report: Prevalence Trend of Transmitted Drug Resistance in a Prospective Cohort of Thai People With Acute HIV Infection.

Authors:  Camilla Muccini; Suteeraporn Pinyakorn; Sunee Sirivichayakul; Eugene Kroon; Carlo Sacdalan; Trevor A Crowell; Rapee Trichavaroj; Jintanat Ananworanich; Sandhya Vasan; Nittaya Phanuphak; Donn J Colby
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-15       Impact factor: 3.771
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.